$IMMU - On our watch/trading lists. This is a good bet we think for getting a new drug approved in the first half of 2020.Immunomedics analyst commentary at Piper JaffrayImmunomedics price target raised to $25 from $20 at Piper Jaffray. Piper Jaffray analyst Joseph Catanzaro raised his price target for Immunomedics to $25 from $20 after hosting meetings with management. The analyst came away "a bit more confident" in a Q2 of 2020 approval for sacituzumab govitecan. Immunomedics emphasized that since the Complete Response Letter it has undertaken a holistic overhaul of manufacturing and that the FDA is in alignment and seemingly eager to get this re-submission filed with no indication that it wants to see confirmatory Ascent data ahead of potential approval, Catanzaro tells investors in a research note. He keeps an Overweight rating on the shares. $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page